Hormonal approaches in prostate cancer : Application in the contemporary prostate cancer patientBEEKMAN, Kathleen W; HUSSAIN, Maha.Urologic oncology. 2008, Vol 26, Num 4, pp 415-419, issn 1078-1439, 5 p.Conference Paper

Optimal Pharmacotherapeutic Management of Hormone-Sensitive Metastatic Prostate CancerALVA, Ajjai; HUSSAIN, Maha.Drugs (Basel). 2013, Vol 73, Num 14, pp 1517-1524, issn 0012-6667, 8 p.Article

Epothilones and the next generation of phase III trials for prostate cancerBHANDARI, Manish S; HUSSAIN, Maha.BJU international (Papier). 2005, Vol 96, Num 3, pp 296-302, issn 1464-4096, 7 p.Article

The evolving role of systemic therapy in high risk prostate cancer: strategies for cure in the 21st centuryVAISHAMPAYAN, Ulka; HUSSAIN, Maha.Critical reviews in oncology/hematology. 2002, Vol 42, Num 2, pp 179-188, issn 1040-8428Article

Chemotherapy for prostate cancer : implementing early systemic therapy to improve outcomesMACVICAR, Gary R; HUSSAIN, Maha.Cancer chemotherapy and pharmacology. 2005, Vol 56, issn 0344-5704, s69-s77, SUP1Article

Current understanding of the biology of advanced bladder cancerAI-SUKHUN, Sana; HUSSAIN, Maha.Cancer. 2003, Vol 97, Num 8, pp 2064-2075, issn 0008-543X, 12 p., SUPConference Paper

Management of Bladder Cancer: Current and Emerging StrategiesAGARWAL, Neeraj; HUSSAIN, Maha.Drugs (Basel). 2009, Vol 69, Num 9, pp 1173-1187, issn 0012-6667, 15 p.Article

A new era in prostate cancer therapy : new targets and novel therapeuticsBRADLEY, Deborah A; HUSSAIN, Maha; STERNBERG, Cora N et al.Targeted oncology. 2008, Vol 3, Num 1, pp 31-39, issn 1776-2596, 9 p.Article

New molecular targets and novel agents in the treatment of advanced urothelial cancerBEEKMAN, Kathleen W; BRADLEY, Deborah; HUSSAIN, Maha et al.Seminars in oncology. 2007, Vol 34, Num 2, pp 154-164, issn 0093-7754, 11 p.Article

Predicting response to hormonal therapy and survival in men with hormone sensitive metastatic prostate cancerGRIVAS, Petros D; ROBINS, Diane M; HUSSAIN, Maha et al.Critical reviews in oncology/hematology. 2013, Vol 85, Num 1, pp 82-93, issn 1040-8428, 12 p.Article

Molecular biology of transitional cell carcinomaAL-SUKHUN, Sana; HUSSAIN, Maha.Critical reviews in oncology/hematology. 2003, Vol 47, Num 2, pp 181-193, issn 1040-8428, 13 p.Article

An active regimen of weekly paclitaxel and estramustine in metastatic androgen-independent prostate cancerVAISHAMPAYAN, Ulka; FONTANA, Joseph; WEI DU et al.Urology (Ridgewood, NJ). 2002, Vol 60, Num 6, pp 1050-1054, issn 0090-4295, 5 p.Article

Phase II evaluation of paclitaxel, α-interferon, and cis-retinoic acid in advanced renal cell carcinomaVAISHAMPAYAN, Ulka; FLAHERTY, Lawrence; WEI DU et al.Cancer. 2001, Vol 92, Num 3, pp 519-523, issn 0008-543XArticle

Should intermittent androgen deprivation be used in routine clinical practice?BHANDARI, Manish S; CROOK, Juanita; HUSSAIN, Maha et al.Journal of clinical oncology. 2005, Vol 23, Num 32, pp 8212-8218, issn 0732-183X, 7 p.Article

International Conference on Androgenic Hormones, Prostate Cancer, and Benign Prostatic HyperplasiaHUSSAIN, Maha; MONTIE, James.The Prostate. 1996, issn 0270-4137, 103 p., SUP6Conference Proceedings

Novel gemcitabine-containing triplets in the management of urothelial cancerHUSSAIN, Maha; VAISHAMPAYAN, Ulka; SMITH, David C et al.Seminars in oncology. 2002, Vol 29, Num 1, pp 20-24, issn 0093-7754, SUP3Article

Cellular biology of prostatic growth factorsPEEHL, D. M.The Prostate. 1996, pp 74-78, issn 0270-4137, SUP6Conference Paper

Neuroendocrine differentiation and hormone-refractory prostate cancerABRAHAMSON, P.-A.The Prostate. 1996, pp 3-8, issn 0270-4137, SUP6Conference Paper

Benign prostatic hyperplasia : A review of its histogenesis and natural historyOESTERLING, J. E.The Prostate. 1996, pp 67-73, issn 0270-4137, SUP6Conference Paper

Growth factors as mediators of androgen action during male urogenital developmentCUNHA, G. R.The Prostate. 1996, pp 22-25, issn 0270-4137, SUP6Conference Paper

Provocative aspects of androgen geneticsBROWN, T. R.The Prostate. 1996, pp 9-12, issn 0270-4137, SUP6Conference Paper

Role of dihydrotestosterone in androgen actionWILSON, J. D.The Prostate. 1996, pp 88-92, issn 0270-4137, SUP6Conference Paper

Role of androgen in prostate growth and regression : Stromal-epithelial interactionCHUNG LEE.The Prostate. 1996, pp 52-56, issn 0270-4137, SUP6Conference Paper

Phase II trial of combination nab -paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinomaALVA, Ajjai; DAIGNAULT, Stephanie; SMITH, David C et al.Investigational new drugs. 2014, Vol 32, Num 1, pp 188-194, issn 0167-6997, 7 p.Article

The patient with hormone-refractory prostate cancer: Determining who, when, and how to treatKENT, Elizabeth C; HUSSAIN, Maha H. A.Urology (Ridgewood, NJ). 2003, Vol 62, Num 6B, pp 134-140, issn 0090-4295, 7 p.Article